A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT03462719 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03462719
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-17
- Primary completion
- 2021-02-26
- Enrollment
- 211
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.